Vascular pharmacology of a novel cannabinoid‐like compound, 3‐(5‐dimethylcarbamoyl‐pent‐1‐enyl)‐<i>N</i>‐(2‐hydroxy‐1‐methyl‐ethyl)benzamide (VSN16) in the rat

Abstract

VSN16 is an agonist at a novel cannabinoid receptor of the vasculature. It acts on the endothelium to release nitric oxide and activate KCa and TRPV1. As it is water-soluble it might be useful in bringing about peripheral cannabinoid-like effects without accompanying central or severe cardiovascular responses.